Phase 1 N=19 Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function
HIV
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total) — 138169.7; 170105.6 h*ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=121 A Lifestyle Physical Activity Intervention for Older Sedentary Women
Coronary Heart Disease
Primary: Accelerometer Vector Magnitude Counts — 345,000; 324,000; 324,000; 309,000 Vector Magnitude Counts — p=0.023
N/A N=236 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 70.6 percentage of participants
N/A N=290 Effects of Ambulation During First Stage of Labour on Maternal and Neonatal Outcomes
Labor Pain
Primary: Duration of the First Stage of Labour — 548.337; 719.585 minutes
N/A N=40 Effects of Biofeedback in Patients With Acute Cerebral Infarction
Acute Ischemic Stroke · Biofeedback · Autonomic Dysfunction, Cognitive Function
Primary: Changes From Baseline Psychological Distress (Anxiety and Depression) at 1 and 3 Months — 14.74; 14.75; 13.11; 14.25 score on a scale
N/A N=59 Internet-based Behavioral Pain Management
Chronic Low Back Pain
Primary: Multidimensional Pain Inventory Interference Subscale — 0.53 score on a scale — p=0.008
Phase 1 N=30 Hyaluronidase Effect on Infusion Set Life
Type 1 Diabetes Mellitus
Primary: Duration of Insulin Infusion Set Wear as a Measure of the Effect of Hyaluronidase Treatment — 5.7; 5.4 Days of wear
Phase 2 N=73 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 35 percent of patients
N/A N=60 Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Asthma
Primary: Spirometry, Percentage Change in FEV1 From Baseline — -1.0; -4.8; -2.2; -7.4 percentage change in FEV1 from baseline — p=<0.05
N/A N=330 Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression
Depression
Primary: Functional Status — 32.1; 31.4; 36.2; 37.3 score on a scale — p=<0.05
N/A N=630 Stand & Move at Work
Obesity · Hypertension · Diabetes
Primary: Mean Change in Light-intensity Physical Activity at Work From Baseline to 12 Months — -0.2; 2.0 Mean change, minutes per 8hr workday
N/A N=1,769 Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Metastatic Renal Cell Carcinoma
Primary: Overall Survival — 52.1; 31.5; 9.8 months
N/A N=180 Fibre-optic Guided Tracheal Intubation Through SADs
Intubation; Difficult or Failed · Laryngeal Masks · Airway Management
Primary: Total Intubation Time to Perform Fibreoptic Intubation — 54.3; 52.0 seconds
N/A N=103 Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up
Diabetes Mellitus · Hypertension · Ischemic Heart Disease
Primary: Exploring Insulin Sensitivity After 10-20 Years of Follow-up — 7 mg/kg/min — p=<0.05
N/A N=30 Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING]
Upper GI Bleeding
Primary: Number of Participants With (Serious) Adverse Event Related to the Medical Device — 0 Participants